FluoGuide announces FG001 meets primary endpoint in phase llb trial in aggressive brain cancer

All patients receiving FG001 had additional cancer detected by optical guidanceFG001 was safe and well tolerated in all patientsCopenhagen, Denmark – FluoGuide A/S , a pioneer in the cutting-edge...

Related Keywords

Denmark ,Copenhagen ,Køavn ,Jane Skj ,Morten Albrechtsen ,Fluoguideas Fluoguide ,Andreas Kjaer ,Christian Binder ,Department Of Neurosurgery At Rigshospitalet ,Chief Physician ,Principal Investigator ,Chief Scientific Officer ,Drug Designation ,Chief Executive Officer ,Markets ,